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Abstract — Bone morphogenetic protein-2 (BMP-2) has 
the ability to induce osteoblast differentiation of 
undifferentiated cells, resulting in the healing of skeletal 
defects when delivered with a suitable carrier.  We have 
applied a versatile delivery platform comprising a novel 
composite of two biomaterials with proven track 
records – apatite and poly(lactic-co-glycolic acid) 
(PLGA) – to the delivery of BMP-2.  Sustained release 
of this growth factor was tuned with variables that 
affect polymer degradation and/or apatite dissolution, 
such as polymer molecular weight, polymer 
composition, apatite loading, and apatite particle size.  
The effect of released BMP-2 on C3H10T1/2 murine 
pluripotent mesenchymal cells was assessed by tracking 
the expression of osteoblastic makers, alkaline 
phosphatase (ALP) and osteocalcin.  Release media 
collected over 100 days induced elevated ALP activity 
in C3H10T1/2 cells.  The expression of osteocalcin was 
also upregulated significantly.  These results 
demonstrated the potential of apatite-PLGA composite 
particles for releasing protein in bioactive form over 
extended periods of time.   
 
Index Terms — Composite, apatite, PLGA, bone 
morphogenetic protein  
I. INTRODUCTION 
urrent treatment of bone defects due to trauma, cancer, 
or degenerative spine diseases involves the 
implantation of a bone graft.  Autografts, which are 
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harvested from the patient’s own body, are associated with 
problems of limited availability and pain at the harvest site.  
The use of allografts obtained from donors is also not 
desirable due to the risks of disease transmission and the 
costs of maintaining bone banks [1].  The ideal solution 
would be to regenerate bone to fill the defects.  A group of 
potent growth factors known as bone morphogenetic 
proteins (BMPs) have been hailed as alternatives to bone 
grafts due to their ability to elicit new bone formation [2-8].  
Clinical use of BMPs involves loading the protein solution 
onto collagen sponges and subsequent implantation [9, 10].  
However, these conventional collagen carriers show rapid 
clearance of BMPs within ~ 2 weeks, whereas bone healing 
is a longer process, especially in higher mammals.  The 
poor retention of BMPs in collagen sponges may explain 
the greater variability in higher mammals’ response to 
BMP, ranging from full bone bridging within weeks to no 
bone union [11].  Hence, the motivation for our research is 
to develop new carriers to more efficaciously deliver these 
expensive therapeutic proteins to achieve bone healing. 
To this end, we have devised a novel composite of two 
biomaterials with proven track records: poly(lactic-co-
glycolic acid) and apatite [12].  The controlled release 
strategy is based on the use of a biodegradable polymer 
with acidic degradation products to control the dissolution 
of the basic apatitic component.  Proteins are pre-adsorbed 
onto the apatitic component such that as the apatite 
dissolves, proteins are released.  The release profile can be 
modified systematically by changing variables that affect 
polymer degradation or apatite dissolution, such as polymer 
molecular weight, polymer hydrophobicity, apatite loading, 
and apatite particle size. 
In this paper, we describe the application of apatite-
polymer composite particles to the delivery of BMP-2.  The 
bioactivity of the released BMP-2 was assessed using a 
pluripotent murine embryonic fibroblast cell line, 
C3H10T1/2, which can be induced to differentiate along 
osteoblast, chondrocyte, adipocyte or myoblast lineages, 
depending on the signals provided.  BMP-2 promotes the 
development of the osteoblast phenotype in these cells, as 
measured by increased expression of alkaline phosphatase 
(ALP), osteocalcin, and other osteoblastic markers [13-17].   
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II. EXPERIMENTAL 
A. Aseptic Preparation of RhBMP-2-Loaded Composite 
Microparticles 
Recombinant human BMP-2 (rhBMP-2) was obtained 
from R&D Sytems.  Composite microparticles 
encapsulating rhBMP-2 were synthesized under aseptic 
conditions by a solid-in-oil-in-water (S/O/W) emulsion 
process [12].  A typical synthesis involved dissolving 250 
mg of PLGA (Alkermes) in 2 ml of dichloromethane.  The 
polymer solution was sterile filtered through a 0.45-µm 
Teflon membrane into a vial containing carbonated apatite 
pre-adsorbed with rhBMP-2.  The mixture was vortexed to 
create a solid-in-oil suspension, which was then transferred 
to 50 ml of 0.1 w/v% methyl cellulose solution that had 
been autoclaved.  An S/O/W suspension was formed by 
homogenizing at 8000 rpm for 2 min at room temperature.  
To solidify the composite particles, dichloromethane was 
evaporated by heating the suspension at 30°C for 3 h.  The 
particles were collected by centrifugation, washed with 
sterile water, and freeze-dried. 
   
B. Evaluation of In Vitro Release 
Release studies were conducted in Eagle’s basal medium 
(BME; Sigma) supplemented with 10 v/v% heat-inactivated 
fetal bovine serum (Invitrogen) and 1 v/v% antibiotics (100 
IU/ml penicillin and 100 µg/ml streptomycin; ATCC).  This 
medium will be referred to as ‘complete BME’.  RhBMP-2-
loaded composite particles were suspended at a 
concentration of 20 mg/ml in complete BME and incubated 
at 37°C.  At pre-determined time intervals (1, 4, 7, 10, 14, 
18, 22, 26, 30 days, up to 100 days), the samples were 
centrifuged, and the supernatant was withdrawn completely 
and replaced with an appropriate volume of fresh medium.  
The collected supernatant was filtered and stored at -20°C 
until evaluation by a BMP-2 sandwich enzyme-linked 
immunosorbent assay (ELISA) kit (R&D Systems).  The 
assay consisted of adding 50 µl of standards and test 
samples to a 96-well plate coated with anti-BMP-2 
monoclonal antibody.  The plate was incubated at room 
temperature for 2 h and washed.  Biotinylated anti-BMP-2 
antibody was then added, and the plate was further 
incubated for 2 h.  Unbound antibody was removed by 
washing, following which streptavidin-horse radish 
peroxidase was introduced.  After 30 min, color was 
developed by the addition of hydrogen peroxide and 
tetramethylbenzidine.  Absorbance was read at 450 nm 
using a UV-Vis microplate reader (VersaMax, Molecular 
Devices) with wavelength correction at 570 nm.  The 
concentration of the protein released at each time point was 
used to construct cumulative release profiles. 
 
C. Cellular Response 
A murine pluripotent embryonic fibroblastic cell line, 
C3H10T1/2, was obtained from ATCC.  The cell line was 
maintained in complete BME.  Cells were expanded in T-
75 flasks at a density of 2000 cells/cm2 with two medium 
renewals per week.  Subculturing was performed before 
cells reached confluence due to the sensitivity of these cells 
to contact and the post-confluence inhibition of cell 
division.  0.25% trypsin/0.53 mM EDTA (ATCC) was used 
to dissociate cells, which were then plated onto 24-well 
plates for in vitro experiments.  Cells from the 11th to 15th 
passages were used. 
 
1) Effect of Release Medium Collected at Each Time Point 
Different sets of rhBMP-2-loaded composite 
microparticles were incubated at 37°C in complete BME at 
a concentration of 20 mg/ml.  Blank composite particles 
prepared under the same processing and material conditions 
but without rhBMP-2 served as controls.  The medium was 
renewed every 3–4 days as described in Section II-B.  The 
release medium collected at each time point was stored at 
-20°C until incubation with cells.  As a standard for 
comparison, Helistat® collagen sponges (Integra Life 
Sciences) were soaked with rhBMP-2 solution for 10–15 
min based on protocols in clinical use [9, 18].  Loaded and 
blank (control) sponges were then transferred into complete 
BME for release studies.   
   Alkaline phosphatase (ALP) activity was determined by 
a modification of the protocol of Lowry et al. [19].  
C3H10T1/2 cells were seeded on 24-well plates at a density 
of 6000 cells/cm2 (~ 12,000 cells/well).  The cells were 
allowed to adhere overnight for 16 h.  The medium was 
aspirated and replaced with 0.5 ml per well of release 
medium from a specific time point.  For each time point, 5 
wells were prepared.  In addition, complete BME enriched 
with 0–2 µg/ml of rhBMP-2 was incubated with cells.  For 
each rhBMP-2 concentration, 5 wells of cells were tested, 
each containing 0.5 ml of enriched BME.  This experiment 
was intended to establish the bioactivity of rhBMP-2 as 
well as to evaluate dose-dependent cellular response. 
 After 4 days of culture, the cells were rinsed twice with 
phosphate-buffered saline (PBS; Gibco) and the plates were 
blotted dry.  The cells were lysed according to the protocol 
provided by R&D Systems.  100 µl of 0.1% Triton X-100 
solution (Sigma) containing 150 mM of NaCl and 3 mM of 
NaHCO3 (pH 9.3) were added to each well.  The plates 
were incubated at 37°C for 30 min.  25 µl of the cell lysate 
were assayed in duplicate for ALP activity using 100 µl of 
p-nitrophenyl phosphate substrate solution (pNPP; Sigma) 
in 96-well plates.  The absorbance at 405 nm was read 
every 5 min for 30 min at 37°C.  ALP cleaves the 
phosphate off pNPP to form p-nitrophenol.  Using Beer’s 
Law and an extinction coefficient of 18.45 cm·L/mmol for 
p-nitrophenol, the amount (in nmol) of p-nitrophenol 
formed per minute was determined.  ALP activity was 
normalized by the protein concentration of the lysate as 
determined by total protein assay (Pierce) and expressed as 
nmol/min·mg protein.  ALP activity induced by the medium 
collected at each time point was plotted as a function of 
time.  Data were plotted as mean ± standard deviation.  
Statistical analysis was performed using Student’s t-test.  A 
significance level of p < 0.05 was used. 
 
  
2) Effect of Prolonged Exposure to Release Medium 
Based on results from in vitro release and induced ALP 
activity at each time point, a set of composite 
microparticles with a sustained release profile of bioactive 
rhBMP-2 was chosen.  This set of composite particles was 
constructed of 59 kD PLGA and 0.08 mg of carbonated 
apatite per mg of PLGA.  RhBMP-2 loading in the particles 
was 145 ng per mg carrier.  The effect of prolonged 
exposure of C3H10T1/2 cells to release medium from this 
set of particles was studied.  As before, the composite 
microparticles were incubated at 37°C in complete BME at 
a concentration of 20 mg/ml.  C3H10T1/2 cells were 
seeded in 24-well plates at a density of 6000 cells/cm2.  
Twice per week, the medium in the wells was aspirated and 
replaced with 0.5 ml of filtered release medium collected 
from the particles.  Release medium from blank composite 
particles served as controls.  For comparison, complete 
BME systems enriched with fixed concentrations of 
rhBMP-2 (10 and 100 ng/ml; 0.5 ml per well) were used.  
Cell culture was conducted for 8 weeks in all groups. 
 At 1, 2, 3, 4, 6 and 8 weeks, cells in 4 wells for each 
group were lysed, and the ALP activity of the cell lysate 
was measured.  At each week, the osteocalcin level of the 
conditioned medium of 4 wells in each group was assayed 
by sandwich ELISA (Biomedical Technologies, Inc.).  The 
procedure for this ELISA was similar to that of the BMP-2 
assay.  Statistical analyses of ALP and osteocalcin levels 
were performed using Student’s t-test.  A significance level 
of p < 0.05 was used. 
III. RESULTS AND DISCUSSION 
A. Effect of Material and Processing Parameters on the In 
Vitro Release of RhBMP-2 from Composite Microparticles 
 
1) Polymer Molecular Weight 
0
1
2
3
4
5
6
7
8
0 20 40 60 80 100
Time (days)
Cu
m
u
la
tiv
e 
BM
P-
2 
Re
le
as
e 
(ng
/m
g 
ca
rr
ie
r)
13 kD
6, 13, 24, 59, 75 kD
blend
59 kD
 
Fig. 1.  Effect of PLGA molecular weight on rhBMP-2 
release.  Composite particles were loaded with 65 ng of 
rhBMP-2 per mg of carrier.     
  
PLGA of lower molecular weight degraded more 
quickly, and hence, enhanced apatite dissolution and 
rhBMP-2 release from composite microparticles (Fig. 1).  
By using an equi-portion blend of PLGA of different 
molecular weights, the production of acidic degradation 
products was equalized over time, leading to a more 
gradual and sustained release of rhBMP-2. 
 
2) Apatite Particle Size 
RhBMP-2 was adsorbed onto carbonated apatite of two 
particle sizes: 1 µm and 7 µm.  The apatite-rhBMP-2 
complexes formed were subsequently incorporated into 
separate sets of composite microparticles.  Apatite particle 
size was found to have a pronounced effect on rhBMP-2 
release (Fig. 2).  The smaller apatite particles presented a 
larger proportion of rhBMP-2 on their surface than within 
their pores due to their higher surface/volume ratio.  As the 
apatitic surface was eroded by acidic degradation products, 
1 µm-sized particles released larger amounts of rhBMP-2 
than 7 µm-sized particles (Fig. 2). 
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Fig. 2.  Effect of apatite particle size on rhBMP-2 release.  
Composite particles were fabricated from 59 kD PLGA and 
contained 65 ng of rhBMP-2 per mg of carrier.     
 
3) Apatite Loading 
When the amount of rhBMP-2 was held constant while 
the loading of apatite in composite microparticles was 
varied from 18 to 45 mg per 250 mg of polymer, rhBMP-2 
release was found to decrease with increasing apatite 
loading (Fig. 3).  For the release of a fixed amount of 
protein, a higher apatite loading requires a larger amount of 
apatite to be dissolved, corresponding to a greater extent of 
polymer degradation.  In addition, apatite served as a 
buffer, mitigating the acidity within the composite particles 
and diminishing the autocatalytic effect of pH on polymer 
hydrolysis.  Hence, the apatite served towards dampening 
the protein release. 
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Fig 3.  Effect of apatite loading (per 250 mg of polymer) on 
rhBMP-2 release.  Composite particles were fabricated 
from 59 kD PLGA and contained 65 ng of rhBMP-2 per 
mg of carrier.   
 
4) Polymer Hydrophobicity 
Increasing polymer hydrophobicity by the addition of 
PLA led to a surprising observation: rhBMP-2 release was 
enhanced with increasing polymer hydrophobicity (Fig. 4).   
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Fig. 4.  Effect of polymer hydrophobicity on rhBMP-2 
release.  Composite particles contained 145 ng of rhBMP-2 
per mg of carrier.  Molecular weights of PLGA and PLA 
were 59 kD and 25 kD, respectively. 
 
Polymer hydrophobicity was expected to reduce water 
penetration and polymer degradation, and hence, decrease 
protein release.  The unexpected result could be explained 
by considering the release of structurally intact, biologically 
active protein versus the total release of protein.  The 
determination of rhBMP-2 concentration by ELISA is 
highly specific; rhBMP-2 molecules have to be of the 
appropriate conformation for binding to antibodies.  
Denatured rhBMP-2 molecules are not detected, as 
confirmed by our previous experience with the evaluation 
of rhBMP-2 concentration in citrate buffers of low pH – the 
low pH led to rhBMP-2 denaturation and poor detection by 
ELISA.  Therefore, higher polymer hydrophobicity could 
have led to a less aggressive pH environment within the 
composite microparticles, contributing to less protein 
denaturation and greater release of bioactive rhBMP-2. 
 
B.  Effect of Conditioned Medium Collected at Each Time 
Point 
The induction of ALP activity in C3H10T1/2 cells by 
different concentrations of rhBMP-2 over 4 days was 
examined.  Increasing the concentration of rhBMP-2 from 0 
ng/well to 200 ng/well (400 ng/ml) was found to elevate 
ALP activity (Fig. 5).  At rhBMP-2 concentrations beyond 
200 ng/well, the effect reached saturation.  Thus, there 
appeared to be an optimum dosage of rhBMP-2 for evoking 
ALP expression, which was related to the commitment of 
undifferentiated cells to the osteoblast lineage. 
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Fig. 5.  Effect of rhBMP-2 concentration on induced ALP 
activity in C3H10T1/2 cells.  Each well contained 0.5 ml of 
medium; 50 ng/well is equivalent to 100 ng/ml of rhBMP-
2. 
 
Levels of ALP activity induced by release media 
collected from rhBMP-2-loaded composite microparticles 
are plotted in Figs. 6–8.  An asterisk denotes statistical 
significance of p < 0.05 by Student’s t-test for n = 5.  
Cumulative release is given in units of ‘ng/well’ to reflect 
the actual amounts to which the cells were exposed, and to 
facilitate comparison with Fig. 5. 
Fig. 6 shows that the release media collected over a 
period of 100 days was able to induce elevated ALP 
expression in C3H10T1/2 cells.  These encouraging results 
suggested that the released rhBMP-2 retained at least part 
of its biological activity and that the release of bioactive 
rhBMP-2 over extended periods of time was possible.  The 
experiment was halted at 100 days, but we speculate that 
this set of composite microparticles could release bioactive 
rhBMP-2 for even longer periods of time since the 
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cumulative release and bioactivity of rhBMP-2 appeared to 
be experiencing an upturn at 100 days (Fig. 6). 
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Fig. 6.  ALP activity induced by release medium collected 
at each time point from rhBMP-2-loaded composite 
microparticles.  Particles contained 145 ng of rhBMP-2 per 
mg of carrier, and were fabricated from 59 kD PLGA and 
0.08 mg of carbonated apatite per mg of PLGA. 
 
When a higher apatite loading was used in the composite 
microparticles, rhBMP-2 release was dampened, and the 
capacity for ALP induction declined within the first week 
(Fig. 7).  In contrast, when rhBMP-2 release was 
augmented and prolonged by using a 3:2 blend of PLGA 
and PLA in the composite microparticles, ALP expression 
was significantly elevated throughout the course of the 
study (Fig. 8). 
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Fig. 7.  ALP activity induced by release medium collected 
at each time point from rhBMP-2-loaded composite 
microparticles.  Particles contained 145 ng of rhBMP-2 per 
mg carrier, and were fabricated from 59 kD PLGA and 0.18 
mg of carbonated apatite per mg of PLGA. 
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Fig. 8.  ALP activity induced by release medium collected 
at each time point from rhBMP-2-loaded composite 
microparticles.  Particles contained 145 ng of rhBMP-2 per 
mg carrier, and were fabricated from a 3:2 blend of 59 kD 
PLGA and 25 kD PLA.  Apatite loading was 0.08 mg of 
carbonated apatite per mg of polymer. 
 
However, the induction of ALP activity was not a simple 
function of the amount of rhBMP-2 released.  This was 
made apparent by our experiments with Helistat® collagen 
sponges, which were the conventional BMP carriers used in 
spinal fusions.  As depicted in Fig. 9, rhBMP-2 release 
from Helistat® sponges was approximately twice the 
magnitude of that from composite microparticles shown in 
Fig. 8.   
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Fig. 9.  ALP activity induced by release medium collected 
at each time point from rhBMP-2-loaded Helistat sponges.  
Sponges contained 200 ng of rhBMP-2 per mg carrier. 
 
Nevertheless, the level of ALP expression was lower, 
and tapered off after 2 weeks, despite the continued release 
of rhBMP-2.  It is unclear what caused the lowered 
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bioactivity of rhBMP-2 released from these sponges.  The 
experiment was repeated to ascertain the validity of these 
results, and the same drop-off in ALP activity was observed 
for both trials. 
 
C. Effect of Prolonged Exposure to Conditioned Medium 
 
1) Measurement of Induced Alkaline Phosphatase Activity 
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Fig. 10.  Effect of length of exposure to rhBMP-2 on ALP 
activity.  rhBMP-2 concentrations of 0 (control), 5 and 50 
ng/well were used. 
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Fig. 11.  Effect of prolonged exposure to release medium 
collected from rhBMP-2-loaded composite microparticles 
on ALP activity.  Particles contained 145 ng of rhBMP-2 
per mg of carrier, and were fabricated from 59 kD PLGA 
and 0.08 mg of carbonated apatite per mg of PLGA. 
 
Compared against controls with no exposure to rhBMP-
2, prolonged exposure of C3H10T1/2 cells to the growth 
factor resulted in elevated levels of ALP expression (Fig. 
10).  However, the increase was not monotonic; ALP 
activity reached a maximum at ~ 2 weeks and then dropped 
to levels that were maintained over the remainder of the 
experiment.  Similar profiles were reported by Shea et al., 
who studied the effect of BMP-7 on C3H10T1/2 cells and 
observed a peak in ALP activity at 8 days [20].  Fig. 10 
also shows a dose-dependent response to rhBMP-2; 50 ng 
of rhBMP-2 per well induced higher levels of ALP activity 
than 5 ng/well. 
The culture of C3H10T1/2 cells with release medium 
collected from rhBMP-2-loaded composite microparticles 
produced a similar effect.  ALP activity was considerably 
raised in the first 2 weeks, and then slowly declined to 
levels comparable to the controls at the end of 8 weeks 
(Fig. 11). 
 
2) Measurement of Osteocalcin Expression 
Osteocalcin is a later stage marker of osteoblast 
differentiation associated with matrix maturation and 
mineralization.  RhBMP-2 was found to upregulate 
osteocalcin expression in C3H10T1/2 cells in a time- and 
dose-dependent manner (Fig. 12).  Control cells with no 
exposure to rhBMP-2 showed low osteocalcin levels, 
particularly at the start of the experiment.  5 ng of rhBMP-2 
per well produced a weak response, which became 
statistically insignificant (p > 0.05) at 7 weeks.  A more 
robust response was obtained with 50 ng of rhBMP-2 per 
well.  Osteocalcin levels experienced doubling in the first 3 
weeks, held steady for the next 4 weeks, and then peaked 
again at week 8.  
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Fig. 12.  Effect of length of exposure to rhBMP-2 on 
osteocalcin levels.  Concentrations used were 0 (control), 5 
and 50 ng of rhBMP-2 per well. 
 
Release medium collected from rhBMP-2-loaded 
composite microparticles had a remarkable effect on 
osteocalcin upregulation.  Osteocalcin levels increased 
steadily with time over 4 weeks, then showed an 
exponential rise from weeks 4 to 7 (Fig. 13).  The level 
reached at week 7 was 10-fold that of the response to 
rhBMP-2-enriched BME (50 ng/well).  These results 
suggested that the cells were undergoing a significant 
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amount of mineralization activity, indicative of an 
osteoblast phenotype.  
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Fig. 13.  Effect of prolonged exposure to release medium 
collected from rhBMP-2-loaded composite microparticles 
on osteocalcin levels.  Particles contained 145 mg of 
rhBMP-2 per mg carrier, and were fabricated from 59 kD 
PLGA and 0.08 mg of carbonated apatite per mg of PLGA. 
IV. CONCLUSIONS 
We have prepared composite microparticles of a 
biodegradable polymer (PLGA) and an inorganic substrate 
(apatite) as delivery vehicles for rhBMP-2.  These 
composite particles were found to be capable of releasing 
bioactive rhBMP-2 over 100 days.  The released growth 
factor induced elevated levels of alkaline phosphatase as 
well as osteocalcin in C3H10T1/2 cells, indicating the 
differentiation of these cells into osteoblasts.   
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